Although a reduction of CXCL13 was demonstrated after DMT treatment in MS patients, some patients still displayed increased CXCL13 CSF levels possibly identifying a subgroup with poorer prognosis [57–59]. This evidence concerns the gene CXCL13 and myeloid sarcoma.